A phase 2 study to confirm safety and efficacy of MB-105, an autologous CD5-directed CAR T-cell therapy, in relapsed/refractory T-cell lymphoma (R/R TCL).

Authors: Swaminathan P. Iyer, Steven M. Horwitz, Salvia Jain, Julie Vose, Aleksandr Lazaryan, Aaron Goodman, Michael Timothy Tees, Anne Beavan, Deepa Jagadeesh, Eric Mou, Andy I. Chen, Malcolm K. Brenner, Helen E. Heslop, Maksim Mamonkin, Sarah Hein, Federica Giordano, Alice Susannah Bexon, LaQuisa C Hill

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps7086

Source: Full article

---

Abstract

TPS7086